We are live on ! Find out more
NVIV

InVivo Therapeutics Holdings Corp
NVIV

Delisted

NVIV was delisted on the 12th of February, 2024.

Back to rankings

20 hedge funds and large institutions have $124K invested in InVivo Therapeutics Holdings Corp in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

11% more funds holding

Funds holding: 18 → 20 (+2)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

83% less capital invested

Capital invested by funds: $720K → $124K (-$596K)

Holders
20
Holders Change
+2
Holders Change %
+11.11%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$25.2K
2
TSS
Two Sigma Securities
New York
+$24.4K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$17.7K
4
Renaissance Technologies
Renaissance Technologies
New York
+$1.71K
5
National Bank of Canada
National Bank of Canada
Quebec, Canada
+$38

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$522K
2
TRCT
Tower Research Capital (TRC)
New York
-$6.38K
3
IA
IFP Advisors
Florida
-$1K
4
UBS Group
UBS Group
Switzerland
-$1K
5
Morgan Stanley
Morgan Stanley
New York
-$59
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$36.8K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$27.8K +$17.7K +9,300 +55%
Millennium Management
3
Millennium Management
New York
$14K +$25.2K +13,280 New
TSS
4
Two Sigma Securities
New York
$13.6K +$24.4K +12,870 New
Renaissance Technologies
5
Renaissance Technologies
New York
$12K +$1.71K +900 +9%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$11.8K – – –
UBS Group
7
UBS Group
Switzerland
$3.96K -$1K -527 -12%
TRCT
8
Tower Research Capital (TRC)
New York
$2K -$6.38K -3,363 -65%
Morgan Stanley
9
Morgan Stanley
New York
$1.56K -$59 -31 -2%
National Bank of Canada
10
National Bank of Canada
Quebec, Canada
$21 +$38 +20 New
Wells Fargo
11
Wells Fargo
California
$14 – – –
TWC
12
TD Waterhouse Canada
Ontario, Canada
$8 +$11 +6 New
Osaic Holdings
13
Osaic Holdings
Arizona
$7 – – –
CTA
14
Colonial Trust Advisors
South Carolina
$2 – – –
FFA
15
Farther Finance Advisors
California
$2 – – –
AF
16
Allworth Financial
California
$2 +$2 +1 New
MIA
17
Milestone Investment Advisors
Wisconsin
$2 +$2 +1 New
SWM
18
Sugarloaf Wealth Management
Georgia
$1 – – –
WP
19
WealthPLAN Partners
Nebraska
$1 +$2 +1 New
AC
20
Armistice Capital
New York
– -$522K -222,000 Closed
IA
21
IFP Advisors
Florida
– -$1K -1 Closed
TF
22
TimeScale Financial
Massachusetts
– -$4 -1 Closed

NVIV Hedge Fund Activity: Q1 2023 in Review

20 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2023, worth a combined $124K — down 83% from $720K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new NVIV positions and 4 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $25.2K. The largest seller was Armistice Capital, exiting entirely with an estimated $522K sold.

  • 20 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2023, up from 18 in Q4 2022.
  • Funds reported $124K of InVivo Therapeutics Holdings Corp stock for Q1 2023, down 83% quarter-over-quarter.
  • 7 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2023 and 4 closed out, a net change of +3 holders.
  • The largest InVivo Therapeutics Holdings Corp buyer in Q1 2023 was Millennium Management, an estimated $25.2K added.
  • The largest InVivo Therapeutics Holdings Corp seller in Q1 2023 was Armistice Capital, an estimated $522K sold.

Based on aggregated 13F filings for Q1 2023.